Peter Mohr

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy

Pierre Squifflet, Everardo D. Saad, Murat Kurt, James Larkin et autres

be, de, se, gb (code pays fourni par la source)

EE509 Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study

Hamid Mahmoudpour, Jürgen C. Becker, Dirk Schadendorf, Ulrike Leiter et autres

Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response

Nalini Srinivas, Ivelina Spassova, Kuan Cheok Lei, Jiwei Gao et autres

de, se (code pays fourni par la source)

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients

Selma Ugurel, Nessr Abu Rached, Thilo Gambichler, Miriam Mengoni et autres

de (code pays fourni par la source)

Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM)

Jürgen Becker, Seyed Hamidreza Mahmoudpour, Dirk Schadendorf, Ulrike Leiter et autres

de (code pays fourni par la source)

Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients

Georg Lodde, Ulrike Leiter, Anja Gesierich, Thomas Eigentler et autres

de, nl (code pays fourni par la source)

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study

Jason J. Luke, Paolo A. Ascierto, Muhammad Adil Khattak, Piotr Rutkowski et autres

us, it, au, pl, es, fr, de, ch (code pays fourni par la source)

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

John M. Kirkwood, Peter Mohr, Christoph Höeller, Jean‐Jacques Grob et autres

us, de, at, fr, it, gb, au (code pays fourni par la source)

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Michael Weichenthal, Eva Ellebæk, Joanna Mangana, Nethanel Asher et autres

de, dk, ch, il, rs, pl, fr, es, bg, us, hr, it, gr, nl (code pays fourni par la source)

Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibition in the non-resectable or metastatic setting – A EUMelaReg real world outcome study

M. Weichenthal, Anne Zaremba, Nethanel Asher, J. Mangana et autres

de, il, ch, bg, es, rs, hr, ba, it, gr, pl (code pays fourni par la source)

Impact of osteoprotective therapies on the efficacy of immune checkpoint inhibition in melanoma patients – A multicentre study from the prospective skin cancer registry ADOReg

Corinna Kochanek, Katrin Schaper‐Gerhardt, Lisa Zimmer, Selma Ugurel et autres

de, us (code pays fourni par la source)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives

Peter Mohr, Inès Nakouri, Sylvie Pfersch, François Denjean et autres

de, fr (code pays fourni par la source)